Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
|Videos|August 24, 2017
Dr. Nanus Discusses Early Stage Kidney Cancer Treatment
Author(s)David Nanus, MD
David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.
Advertisement
David M. Nanus, MD, medical oncologist, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment for patients with early-stage kidney cancer.
Therapies that are showing progress in the advanced setting, such as immunotherapy, may have a place in early-stage cancer, says Nanus.
Advertisement
Related to this article
The FDA has granted 68Ga-NYM096 breakthrough therapy and fast track designations for imaging ccRCC.
Pembrolizumab plus denosumab produced a 31% ORR and 53% 6-month PFS rate in VEGFR TKI–pretreated advanced clear cell renal cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zanidatamab-Based Regimens for First-Line HER2+ Locally Advanced or Metastatic Gastric Cancer
2
Amivantamab Monotherapy Yields Durable Responses in Pretreated R/M HNSCC
3
INTREPID Trial Aims to Advance Sapablursen for Phlebotomy-Dependent Polycythemia Vera
4
Olverembatinib Deepens Efficacy in Second-Line CML
5